CD8A and head and neck squamous cell carcinoma: It acts on immunotherapy agents that enhance K+ channel activity, (Ca2+) fluxes, and CD8+ T-cell chemotaxis in HNSCC patients, with a unique pattern of response in responders that leads to enhanced cytotoxic T-cell functionality [27,28].